Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.53 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: moricizine, moricizine hydrochloride, tetracaine +78 | 1.00 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 6 Parkinson's papers of 2,415 | 0.74 |
| pathways Reactome | 2 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 11470
Earlier readings: 2026-10-26 0.47; 2026-10-25 0.47; 2026-10-24 0.47; 2026-10-23 0.47.
Sealed predictions
- SCN5A in dopamine neurons, braak-0.11 (p 0.773) → -0.19 (p 0.630)receipt 0175
Swarm cases
receipt 0175: SCN5A in dopamine neurons, braak
- power
- full sample -0.12 (p 0.627, n 18), 95% CI -0.56 to +0.36. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.17 (p 0.498, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.21 (p 0.408, n 18). could be the mix.
- skeptic
- leave-one-out range -0.26 to -0.01, sign flips 0; without severely affected donors -0.12 (p 0.627, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for SCN5A in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts